02.19.26 -- End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight

Explore the key differences between traditional DOE and Functional DOE as Seongjin Kim demonstrates how the latter enhances bioprocess optimization through a fed-batch cell culture example.

Explore how infrastructure, equipment strategy, and advanced technologies shape a more reliable path for scaling sterile injectable programs.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

Improving specific productivity moves the goal beyond pumping out higher titers, but it demands a deeper understanding of cellular biology and protein expression.

Onshoring biomanufacturing operations is an increasingly common decision. While a mid-phase tech transfer from international to domestic CDMO can be complex, the right partner can ensure success.

Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.

De-risk the supply chain, accelerate time to market, and reduce costs by selecting an optimal manufacturing strategy and leveraging the right technologies for therapeutic protein production.

Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

Radiofrequency identification (RFID)-based unit-level tracking solutions for prefilled syringes are poised to help pharma manufacturers address key risks and costly bottlenecks related to the fill-finish process.

Consider this manufacturing platform integrating perfusion bioreactors, continuous product capture, low pH viral inactivation, polishing, viral filtration, and formulation steps.

We discuss the trends in new molecular formats, which is one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

Explore how biopharma organizations can design and operate clinical supply systems that absorb complexity while maintaining control and consistency.

Fill‑finish is evolving as biologics and advanced therapies shift capacity and sterility needs. Automation, emerging tech, and data‑driven methods are boosting efficiency in aseptic production.

Biocatalysis delivers cleaner, more selective pharma processes while cutting energy use and waste. Engineered enzymes broaden their reach, enabling faster development and greater sustainability.

Understand how formulation development for a prefilled syringe affects manufacturing, driving the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

Integrated laboratory and in‑silico developability assessments provide early insight into antibody characteristics, reduce risks, streamline decision‑making, and accelerate progress.

Take a behind-the-scenes look at AGC Biologics’ Seattle campus, one of the most established and productive CDMO facilities in the United States.

See how optimized monoclonal antibody capture chromatography — especially resin selection — can improve cost efficiency, scalability, and productivity in therapeutic antibody manufacturing.

Review our full service offering and learn how we can help advance your project toward commercialization with speed and efficiency.

Lonza’s bYlok technology is a true plug-and-play solution to bispecific antibody engineering – high product quality, simplified processes, unlocking the future.